|Table of Contents|

Clinical application progress and thoughts about HPV prophylactic vaccines

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 02
Page:
328-331
Research Field:
Publishing date:

Info

Title:
Clinical application progress and thoughts about HPV prophylactic vaccines
Author(s):
Cheng Lin; Zhang Kun; Xu Tianmin
The Second Hospital of Jilin University,Jilin Changchun 130041,China.
Keywords:
cervical cancer; human papillomavirus; vaccine
PACS:
R730.1
DOI:
10.3969/j.issn.1672-4992.2017.02.045
Abstract:
Cervical cancer is the most common cancer in female genitourinary system.The close relationship between high-risk human papillomavirus(HPV) persistent infection and cervical cancer had been confirmed by epidemiology studies. Hence,HPV vaccine has attracted tremendous attention on preventing HPV infection and cervical lesions. Our review focusd on the three types of HPV prophylactic vaccines which have been approved for marketing by FDA. We also list some controversies which could draw more attention and thought-provoking.

References:

[1]Muňoz N,Castellsagué X,De González AB,et al. Chapter 1: HPV in the etiology of human cancer［J］. Vaccine,2006,24(Suppl 3):S3/1-10.
[2]Juckett G,Hartman-Adams H. Human papillomavirus:Clinical manifestations and prevention［J］. Am Fam Physician,2010,82(10):1209-1213.
[3]Zhai L,Tumban E. Gardasil-9: A global survey of projected efficacy［J］. Antiviral Res,2016,130:101-109.
[4]Bosch FX,Burchel AN,Schiffman M,et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia［J］. Vaccine,2008,26(Suppl 10):K1-16.
[5]Zhou J,Sun XY,Stenzel DJ,et al. Expression of vaccinia recombinant HPV16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles［J］.Virology,1991,185(1):251-257.
[6]Garcon N,Wettendorff M,Van Mechelen M. Role of AS04 in human papillomavirus vaccine:Mode of action and clinical profile［J］. Expert Opin Biol Ther,2011,11(5):667-677.
[7]WHO Guidelines Approved by the Guidelines Review Committee.Comprehensive cervical cancer control: A guide to essential practice.Source 2nd edition［C］. Geneva: World Health Organization,2014.
[8]Saslow D,Andrews KS,Manassaram-Baptiste D,et al. Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement［J］. CA Cancer J Clin,2016,66(5):375-385.
[9]Naud PS,Roteli-Martins CM,De Carvalho NS,et al. Sustained efficacy,immunogenicity,and safety of the HPV-16/18 AS04-adjuvanted vaccine:Final analysis of a long-term follow-up study up to 9.4 years post-vaccination［J］. Hum Vaccin Immunother,2014,10(8):2147-2162.
[10]Paavonen J,Naud P,Salmerón J,et al.Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA):Final analysis of a double-blind,randomised study in young women［J］. Lancet,2009,374(9686):301-314.
[11]Apter D,Wheeler CM,Paavonen J,et al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women:Final event-driven analysis of the randomized,double-blind PATRICIA trial［J］. Clin Vaccine Immuno,2015,22(4):361-373.
[12]Hildesheim A,Wacholder S,Catteau G,et al. Efficacy of the HPV-16/18 vaccine:Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial［J］. Vaccine,2014,32(39):5087-5097.
[13]Kreimer AR,Struyf F,Del Rosario-Raymundo MR,et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine:Combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials［J］. Lancet Oncol,2015,16(7):775-786.
[14]Brotherton JM. Could one dose of bivalent HPV vaccine prevent cervical cancer［J］?Lancet Oncol,2015,16(7):739-740.
[15]Malagón T,Drolet M,Boily MC,et al. Cross-protective efficacy of two human papillomavirus vaccines:A systematic review and Meta-analysis［J］. Lancet Infect Dis,2012,12(10):781-789.
[16]Castle PE,Schmeler KM. HPV vaccination:For women of all ages［J］?Lancet,2014,384(9961):2178-2180.
[17]Godi A,Bissett SL,Miller E,et al. Relationship between humoral immune responses against HPV16,HPV18,HPV31 and HPV45 in 12~15 years old girls receiving Cervarix or Gardasil vaccine［J］. PLoS One,2015,10(10):e0140926.
[18]Tarney C,Pagan M,Klaric J,et al. Immunity for unvaccinated women or cross-protection for nonvaccine HPV types［J］ .Obstet Gynecol,2016，127（Suppl 1）:4S.
[19]Harari A,Chen Z,Rodríguez AC,et al.Cross-protection of the bivalent human papillomavirus(HPV) vaccine against variants of genetically related high-risk HPV infections［J］.J Infect Dis,2016,213(6):939-947.
[20]FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions［J］. N Engl J Med,2007,356(19):1915-1927.
[21]Nygrd M,Saah A,Munk C,et al. Evaluation of the long-term anti-human papillomavirus 6 (HPV6),11,16,and 18 immune responses generated by the quadrivalent HPV vaccine［J］. Clin Vaccine Immunol,2015,22(8):943-948.
[22] Stanley M. Potential mechanisms for HPV vaccine-induced long term protection［J］. Gynecol Oncol,2010,118:S2-S7.
[23]Joura EA,Giuliano AR,Iversen OE,et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women［J］.N Engl J Med,2015,372(8):711-723.
[24]Vesikari T,Brodszki N,Van Damme P,et al. A randomized,double-blind,phase Ⅲ study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil in 9~15-year-old girls［J］.Pediatr Infect Dis J,2015,34(9):992-998.
[25]Van Damme P,Meijer CJ,Kieninger D,et al. A phase Ⅲ clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men［J］.Vaccine,2016,34(35):4205-4212.
[26]Van Damme P,Olsson SE,Block S,et al. Immunogenicity and safety of a 9-valent HPV vaccine［J］.Pediatrics,2015,136(1):e28-39.
[27]Garland SM,Cheung TH,McNeill S,et al.Safety and immunogenicity of a 9-valent HPV vaccine in females 12~26 years of age who previously received the quadrivalent HPV vaccine［J］.Vaccine,2015，33(48):6855-6864.
[28]Kim YJ,Kim KT,Kim JH,et al. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10~14 years［J］.J Korean Med Sci，2010,25(8):1197-1204.
[29]Angioli R,Lopez S,Aloisi A,et al. Ten years of HPV vaccines: State of art and controversies［J］.Crit Rev Oncol Hematol 2016,102:65-72.
[30]Wacholder S,Chen BE,Wilcox A,et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18:Pooled analysis of two randomised controlled trials［J］.BMJ，2010，340:c712.
[31]Garland SM,Ault KA,Gall SA,et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine:A combined analysis of five randomized controlled trials［J］.Obstet Gynecol,2009,114(6):1179-1188.
[32]Tota JE,Ramanakumar AV,Jiang M,et al.Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination［J］.Am J Epidemiol,2013,178(4):625-634.
[33]Wang R,Guo XL,Wisman GB,et al. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China［J］.BMC Infect Dis,2015,15:257.

Memo

Memo:
吉林省计委基金（编号：2014G073，2016C046-2）；吉林省科技厅基金（编号：20150204007YY）
Last Update: 2016-12-01